Dupont Capital Management Corp bought a new stake in Bristol-Myers Squibb Company (NYSE:BMY) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 39,645 shares of the biopharmaceutical company’s stock, valued at approximately $2,209,000.
A number of other hedge funds also recently added to or reduced their stakes in BMY. Blue Chip Partners Inc. grew its position in Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after acquiring an additional 17 shares in the last quarter. Keel Point LLC boosted its position in Bristol-Myers Squibb by 0.3% during the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 18 shares during the period. Staley Capital Advisers Inc. boosted its position in Bristol-Myers Squibb by 0.3% during the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 24 shares during the period. Shayne & CO. LLC boosted its position in Bristol-Myers Squibb by 0.6% during the second quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 24 shares during the period. Finally, Greenleaf Trust boosted its position in Bristol-Myers Squibb by 0.4% during the second quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock valued at $535,000 after buying an additional 39 shares during the period. Institutional investors and hedge funds own 69.14% of the company’s stock.
Bristol-Myers Squibb Company (BMY) traded down $1.13 during midday trading on Friday, hitting $60.86. 5,592,700 shares of the stock traded hands, compared to its average volume of 8,740,103. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Company has a twelve month low of $46.01 and a twelve month high of $66.10. The stock has a market capitalization of $101,459.04, a price-to-earnings ratio of 20.94, a price-to-earnings-growth ratio of 2.44 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same period in the previous year, the company earned $0.77 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 6.7% on a year-over-year basis. analysts forecast that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 6th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is currently 61.42%.
A number of analysts have issued reports on BMY shares. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price target on the stock. in a report on Tuesday, August 22nd. Citigroup Inc. set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 26th. Deutsche Bank AG set a $55.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, July 17th. Finally, Credit Suisse Group set a $58.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Wednesday, August 16th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $64.93.
In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.23% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/11/11/dupont-capital-management-corp-invests-2-21-million-in-bristol-myers-squibb-company-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.